About this trial
PP016 is a FIND-sponsored retrospective clinical performance study evaluating rapid molecular point-of-care (mPOC) tests for the detection of Mpox virus (MPXV) using archived lesion swab specimens collected in Uganda. Conducted at the Central Public Health Laboratory (CPHL) in Kampala, the study compares up to three investigational assays-Genes2Me VZV-Q, KH Medical RADI-ONE Mpox, and SD Biosensor STANDARD M10 MPX/OPX-against the BioPerfectus laboratory PCR reference test. The primary objective is to determine the sensitivity and specificity of each assay for detecting MPXV in archived positive and negative samples, while secondary analyses assess performance by Ct value and viral clade. The study uses a blinded, non-interventional case-control design with de-identified specimens collected since 2020. Approximately 80 samples per device evaluation are included. PP016 was initiated in response to ongoing mpox outbreaks and the need for accurate decentralized diagnostics in low-resource settings. The study complies with ISO 20916, ICH-GCP principles where applicable, and Ugandan ethical and regulatory requirements, with findings expected to support future regulatory approvals and implementation of rapid mpox diagnostics in low- and middle-income countries
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Lesion swabs stored in VTM/UTM (non-inactivating)
Aliquot with sufficient volume to run the reference PCR and at least one index test (≥2600 μL per pair reference-index tests: ideally at least 1400 μL for 3 index tests and 1200 μL for reference PCR, including 1 possible repeat per test)
Available PCR result for specimen selection (i.e. confirmed MPXV positive or negative)
Samples collected from 2020 onwards.
Disqualifiers
Unknown date of collection
>3 freeze-thaw cycles of sample.
Samples collected with expired swab collection devices or UTM/VTM
Trial population
The study population consists of archived skin lesion swabs specimens. These were previously collected from individuals suspected of mpox infection - confirmed by PCR as MPXV positive or negative - under research studies and/or public health surveillance protocols during past and ongoing mpox outbreaks and available in the selected clinical sites.
Trial design
Case-control
Retrospective
Treatments tested in this trial
MPOX IVD test
Diagnostic testEach (negative and positive) sample will be tested on the standard of reference and the investigational IVD
Treatment groups
Trial outcomes
Primary outcomes
Point estimates of sensitivity, specificity, positive and negative predictive value (PPV and NPV respectively) with 95% confidence intervals.
Point estimates of sensitivity, specificity, positive and negative predictive value (PPV and NPV respectively) with 95% confidence intervals.
Secondary outcomes
Point estimates of sensitivity/PPA stratified by Ct values of the reference PCR test.
Point estimates of sensitivity/PPA stratified by Ct values of the reference PCR test.
Point estimates of sensitivity/PPA and specificity/NPA with 95% confidence intervals stratified by virus clade.
Point estimates of sensitivity/PPA and specificity/NPA with 95% confidence intervals stratified by virus clade.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: